Ascendis Pharma and Novo Nordisk Join Forces
Company Announcements

Ascendis Pharma and Novo Nordisk Join Forces

Ascendis Pharma (ASND) has released an update.

Ascendis Pharma has entered a collaboration with Novo Nordisk to license its TransCon technology, aiming to develop treatments for metabolic and cardiovascular diseases, including a monthly TransCon Semaglutide product for obesity and type 2 diabetes. The agreement could bring Ascendis up to $285 million in milestone payments, along with sales-based royalties. Novo Nordisk will handle the clinical development and commercialization, with Ascendis focusing on early-stage research.

For further insights into ASND stock, check out TipRanks’ Stock Analysis page.

Related Articles
TheFlyAscendis Pharma granted Novo exclusive worldwide license to TransCon platform
Catie PowersAscendis Pharma A/S (ASND) Q3 Earnings Cheat Sheet
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App